Teva Pharmaceuticals has successfully completed its $6.2bn acquisition of Cephalon following approval from European regulators.

Following the European Commission approval, Teva will divest marketing rights in France for a generic version of Cephalon narcolepsy medication Provigil.

The move comes after US authorities requested that Teva allow Par Pharmaceuticals to market a separate generic copy of Provigil for a year.

The acquisition has been designed to allow Teva to offset revenue losses associated with the patent expiry of multiple sclerosis drug Copaxone, the company’s biggest selling product.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now